Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly a quarter of Americans say they have trouble paying for medications.
Cost concerns have led many private insurers and public payers to impose restrictions on treatment.
Outlined in a Health Affairs Blog post, the recommendations come from the Treatment Action Group and the Fair Pricing Coalition.
Report by HIV and hepatitis C advocates gives lawmakers and the White House a 100-day road map to tackling drug costs.
#FairDrugPricesNow campaign calls for more transparency among drug companies.
WATCH: A video and campaign by HIV, hepatitis C and LGBT groups to address the rising costs of meds.
The FPC argues that setting a flat price would help ensure patients needing longer treatments would not be restricted from taking the new hep...
The FDA has approved Gilead Sciences’ hotly anticipated new hepatitis C therapy Harvoni (ledipasvir/sofosbuvir).
Getting Obamacare passed and up and running was just the first round in the struggle to bring universal health care to people living with...
“This is a very significant advance.”
The Fair Pricing Coalition is again sounding the alarm regarding the price of newly approved treatments for hepatitis C.
Merck has priced its new hepatitis C drug, Victrelis (boceprevir), out of reach of many of those who need it
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.